Clearmind Medicine said its independent DSMB (Data and Safety Monitoring Board) unanimously approved moving its FDA-regulated Phase I/II trial of CMND-100 into parts B and C after Part A met the study’s primary safety endpoint. The company said CMND-100 showed a favorable safety and tolerability profile across all planned dose levels in healthy participants, supporting the transition into patients with moderate to severe alcohol use disorder for the first time. Part B will sequentially enroll two cohorts of six patients receiving 80 mg and 160 mg doses and will assess safety, tolerability and early signs of clinical activity, including whether CMND-100 may reduce alcohol consumption and craving. Part C will run concurrently in healthy participants, testing a fixed daily 160 mg dose over five consecutive days in a double-blind, placebo-controlled setting to further characterize safety and tolerability. The company said the Phase I/II study is designed to evaluate safety, tolerability, pharmacokinetics (how a drug moves through the body) and preliminary efficacy in reducing drinking patterns and alcohol craving. Trial sites include Johns Hopkins University, Yale School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center. Clearmind said it expects to provide further updates as enrollment progresses. CMND-100 is Clearmind’s oral formulation of MEAI, which the company is developing as a non-hallucinogenic neuroplastogen-derived candidate intended to promote adaptive neuroplasticity while avoiding the perceptual effects linked to classical psychedelics.